JonathanCorrenMD

PubMed

• Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
  Alberto Papi, Mario Castro, Jonathan Corren, Ian D Pavord, Yuji Tohda, Arman Altincatal, Nami Pandit-Abid, Elizabeth Laws, Bolanle Akinlade, Leda P Mannent, Rebecca Ga...> ;Respiratory Medicine. 2024 Apr 1
• Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.
  Ian D Pavord, Thomas B Casale, Mark J FitzGerald, Yamo Deniz, Arman Altincatal, Rebecca Gall, Nami Pandit-Abid, Amr Radwan, Juby A Jacob-Nara, Paul J Rowe, Jonathan Co...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2024 Mar 28
• Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
  Brusselle, G., Sun, L., Siu, K., Wu, W., Corren, J., Szefler, S., Sher, E., Korenblat, P., Soong, W., Hanania, N., Berman, G., Zitnik, R., Natalie, C., Lio, P., Armstr...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2024 Feb 14
• Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
  Matthew F Wipperman, Kaitlyn M Gayvert, Amanda Atanasio, Claire Q Wang, Jonathan Corren, Angelica Covarrubias, Ian Setliff, Erica Chio, Elizabeth Laws, Kelley Wolfe, S...> ;Allergy. 2024 Apr 1
• Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
  Reynold Panettieri Jr, Christopher S Ambrose, Njira Lugogo, Jonathan Corren> ;Journal of Asthma and Allergy. 2024 Jan 1
• Tezepelumab in patients with allergic and eosinophilic asthma.
  Caminati, M., Buhl, R., Kim, H., Korn, S., Lommatzsch, M., Martin, N., Matucci, A., Nasser, S., Pavord, I., Domingo, C., Corren, J., Hanania, N.> ;Allergy. 2023 Dec 26
• Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.
  Anju T Peters, Hironori Sagara, Jonathan Corren, Christian Domingo, Arman Altincatal, Xavier Soler, Nami Pandit-Abid, Nora Crikelair, Paul J Rowe, Juby A Jacob-Nara, Y...> ;Annals of Allergy, Asthma & Immunology. 2024 Apr 1
• 2 citations
  Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
  Jonathan Corren, Andrew Menzies-Gow, Johan Bimmel, Anthony McGuinness, Gun Almqvist, Karin Bowen, Janet M Griffiths, Sandhia Ponnarambil, Arnaud Bourdin, Elliot Israel...> ;Immunotherapy. 2023 Nov 1
• Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
  Jonathan Corren, Nicola A Hanania, William W Busse, Lawrence D Sher, Arman Altincatal, Megan Hardin, Leda P Mannent, Nikhil Amin, David J Lederer, Xavier Soler, Juby A...> ;Clinical and Experimental Allergy. 2023 Oct 1
• Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
  Jonathan Corren, Constance H Katelaris, Mario Castro, Jorge F Maspero, Marc Humbert, David M G Halpin, Arman Altincatal, Nami Pandit-Abid, Xavier Soler, Amr Radwan, Ju...> ;ERJ Open Research. 2023 Sep 1
• 3 citations
  Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
  Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, Christopher S Ambrose, Joseph D Spahn, Stephanie L Roseti, Bill Cook, Janet M Griffiths, Åsa Hellqvist, Nicole Marti...> ;Annals of Allergy, Asthma & Immunology. 2023 Nov 1
• 1 citations
  Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
  Ian D Pavord, Arnaud Bourdin, Alberto Papi, Christian Domingo, Jonathan Corren, Arman Altincatal, Amr Radwan, Nami Pandit-Abid, Juby A Jacob-Nara, Yamo Deniz, Paul J R...> ;Allergy. 2023 Nov 1
• 1 citations
  Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
  Andrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, Elliot Israel, Åsa Hellqvist, Gillian Hunter, Stephanie L Roseti, Christopher S Ambrose, Jean-Pierre Llanos, Bill C...> ;Annals of Allergy, Asthma & Immunology. 2023 Sep 1
• 15 citations
  Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
  Jonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, Elliot Israel, Stephanie Korn, Bill Cook, Christopher S Ambrose, Åsa Hellqvist, Stephanie L Roseti, Nestor A Molfi...> ;American Journal of Respiratory and Critical Care Medicine. 2023 Jul 1
• Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
  Lawrence D Sher, Jonathan Corren, Ian D Pavord, Nadia Daizadeh, Arman Altincatal, Xavier Soler, Michel Djandji, Amr Radwan, Juby A Jacob-Nara, Yamo Deniz, Paul J Rowe> ;The Journal of Asthma. 2023 Sep 1
• 4 citations
  Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
  Jonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, Celeste Porsbjerg, Michael E Wechsler, Andrew Menzies-Gow, Christopher S Ambrose, Bill Cook, Neil Mar...> ;The European Respiratory Journal. 2023 Mar 1
• 26 citations
  Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
  Andrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, Stephanie Korn, Jonathan Corren, Elliot Israel, Geoffrey Chupp, Artur Bednarczyk, Sandhia Ponnarambil...> ;The Lancet. Respiratory Medicine. 2023 May 1
• 1 citations
  Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.
  Tanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, Joseph K Han, Nicole Martin, Elliot Israel, Jason K Lee, Jean-Pierre Llanos, Neil Martin, Ayman Megally, Bhavini Pa...> ;Journal of Asthma and Allergy. 2023 Jan 1
• Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
  Eugene R Bleecker, Reynold A Panettieri Jr, Njira L Lugogo, Jonathan Corren, Nadia Daizadeh, Juby A Jacob-Nara, Yamo Deniz, Paul J Rowe, Angela Khodzhayev, Xavier Sole...> ;Journal of Immunology Research. 2023 Jan 1
• 1 citations
  Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
  Jonathan Corren, David J Jackson, Thomas B Casale, Larry Borish, Klaus F Rabe, William W Busse, Jorge F Maspero, Daniel J Jackson, Nadia Daizadeh, Arman Altincatal, Am...> ;Journal of Asthma and Allergy. 2023 Jan 1
• 15 citations
  Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
  Ian D Pavord, Yamo Deniz, Jonathan Corren, Thomas B Casale, J Mark FitzGerald, Kenji Izuhara, Nadia Daizadeh, Benjamin Ortiz, Robert R Johnson, Sivan Harel, Michel Dja...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2023 Apr 1
• 8 citations
  Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
  Jonathan Corren, Christopher S Ambrose, Janet M Griffiths, Åsa Hellqvist, Andrew W Lindsley, Jean-Pierre Llanos, Gene Colice, Andrew Menzies-Gow> ;Clinical and Experimental Allergy. 2023 Apr 1
• 1 citations
  Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma.
  Jonathan Corren, Michael E Wechsler, Geoffrey Chupp, Stephanie L Roseti, Åsa Hellqvist, Neil Martin, Jean-Pierre Llanos, Christopher S Ambrose, Gene Colice> ;The Journal of Allergy and Clinical Immunology. in Practice. 2023 Mar 1
• 3 citations
  Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States.
  Moisés A Calderon, Thomas B Casale, Harold S Nelson, Leonard B Bacharier, Priya Bansal, David I Bernstein, Michael Blaiss, Jonathan Corren, Lawrence DuBuske, Shahnez F...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2023 Apr 1
• 16 citations
  Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
  Jonathan Corren, David Larson, Matthew C Altman, R Max Segnitz, Pedro C Avila, Paul A Greenberger, Fuad Baroody, Mark H Moss, Harold Nelson, Allison J Burbank, Michell...> ;The Journal of Allergy and Clinical Immunology. 2023 Jan 1
• Join now to see all

Journal Articles

• Editorial How Important Is Adherence to Inhaled Medications Before Starting a Biologic Therapy for Asthma?  
  Jonathan Corren, MD, ScienceDirect